Glucose Health, Inc. Announces Officer Changes Effective September 30, 2025
Glucose Health (OTC: GLUC) announced the resignation of its Chief Executive Officer and Chief Financial Officer, effective September 30, 2025. The departure was voluntary and not requested by the company. Murray Fleming, the company's sole Director, will temporarily assume both roles to maintain administrative continuity and assist in identifying new officers.
Notably, the company disclosed having limited operating capital and expressed uncertainty about its ability to continue as a going concern. The interim leadership arrangement will continue until permanent successors are appointed, the company ceases operations, or the Board takes alternative action regarding officer appointments.
Glucose Health (OTC: GLUC) ha annunciato le dimissioni del suo Amministratore Delegato e del Direttore Finanziario, con effetto dal 30 settembre 2025. La separazione è volontaria e non è stata richiesta dall'azienda. Murray Fleming, l'unico membro del Consiglio, assumerà temporaneamente entrambe le cariche per mantenere la continuità amministrativa e aiutare nell'individuazione di nuovi funzionari.
In particolare, l'azienda ha reso noto di avere capitali operativi limitati e di esprimere incertezza sulla propria capacità di proseguire quali entità operanti. L'attuale schema di leadership rimarrà in vigore fino all'identificazione di successori permanenti, fino alla cessazione delle attività o finché il Consiglio non adotterà altre misure riguardo la nomina dei dirigenti.
Glucose Health (OTC: GLUC) anunció la renuncia de su Director Ejecutivo y Director Financiero, con efecto el 30 de septiembre de 2025. La salida fue voluntaria y no solicitada por la empresa. Murray Fleming, el único Director de la compañía, asumirá temporalmente ambos cargos para mantener la continuidad administrativa y ayudar a identificar nuevos responsables. Notablemente, la empresa divulgó contar con capital operativo limitado y expresó incertidumbre sobre su capacidad para seguir como empresa en funcionamiento. El arreglo de liderazgo interino continuará hasta que se nombren sucesores permanentes, la empresa cese operaciones o la Junta tome medidas alternativas respecto a los nombramientos de directivos.
Glucose Health (OTC: GLUC)는 최고경영자(CEO)와 최고재무책임자(CFO)의 사임을 발표했으며, 효력이 2025년 9월 30일에 발효됩니다. 이 이직은 자발적이며 회사가 요청한 것이 아닙니다. Murray Fleming은 회사의 유일한 이사회 이사로서 임시로 두 직위를 모두 맡아 행정적 연속성을 유지하고 새로운 임원을 찾는 데 도움을 줄 것입니다.
특히 이 회사는 운영 자본이 제한적임을 공개했고, 계속해서 정상 운영될 수 있을지에 대해 불확실성을 표명했습니다. 임시 리더십 체제는 영구 후임자가 임명되거나 회사가 운영을 중단하거나 이사회가 임원 임명에 대해 다른 조치를 취할 때까지 계속됩니다.
Glucose Health (OTC: GLUC) a annoncé la démission de son directeur général et de son directeur financier, effective le 30 septembre 2025. Cette départ est volontaire et non demandé par l'entreprise. Murray Fleming, le seul administrateur de la société, assumera temporairement les deux fonctions afin d'assurer la continuité administrative et d'aider à l'identification de nouveaux responsables.
Notamment, l'entreprise a indiqué disposer d'un capital opérationnel limité et a exprimé son incertitude sur sa capacité à poursuivre ses activités en tant qu'entreprise continue. Le dispositif de direction intérimaire restera en place jusqu'à ce que des successeurs permanents soient nommés, que l'entreprise cesse ses activités, ou que le Conseil prenne des mesures alternatives concernant les nominations des dirigeants.
Glucose Health (OTC: GLUC) gab den Rücktritt seines Chief Executive Officer und Chief Financial Officer bekannt, mit Wirkung zum 30. September 2025. Der Abgang erfolgte freiwillig und nicht auf Verlangen des Unternehmens. Murray Fleming, der einzige Direktor des Unternehmens, wird vorübergehend beide Ämter übernehmen, um die administrative Kontinuität sicherzustellen und bei der Suche nach neuen Führungskräften zu helfen.
Das Unternehmen gab ferner bekannt, dass es über begrenztes Betriebskapital verfüge und äußerte Unsicherheit über seine Fähigkeit, als laufendes Unternehmen fortzufahren. Die Übergangsführung bleibt so lange bestehen, bis dauerhafte Nachfolger ernannt werden, das Unternehmen seine Aktivitäten einstellt oder der Vorstand andere Maßnahmen in Bezug auf die Ernennung von Geschäftsführern ergreift.
Glucose Health (OTC: GLUC) أعلنت عن استقالة رئيسها التنفيذي والمدير المالي، ساري المفعول ابتداءً من 30 سبتمبر 2025. المغادرة كانت طوعية وليست مطلوبة من الشركة. موراي فليمنغ، وهو المدير الوحيد للشركة، سيتولى مؤقتاً كلا المنصبين للحفاظ على الاستمرارية الإدارية ومساعدة في تحديد مسؤولين جدد.
ومن الجدير بالذكر أن الشركة كشفت عن وجود رأس مال تشغيلي محدود وأعربت عن عدم اليقين بشأن قدرتها على الاستمرار كوحدة قيد التشغيل. سيستمر ترتيب القيادة المؤقت حتى يتم تعيين خلفاء دائمين، أو تتوقف الشركة عن العمل، أو يتخذ مجلس الإدارة إجراءً بديلًا بشأن تعيين المدراء.
Glucose Health (OTC: GLUC)宣布其首席执行官及首席财务官辞职，生效日期为2025年9月30日。此次离职为自愿行为，并非公司所要求。Murray Fleming，公司唯一董事，将临时担任两职，以维持行政连续性并协助寻求新的高管人选。
值得注意的是，公司披露拥有有限的运营资金，并对能否继续作为持续经营实体表示不确定。此临时领导安排将持续，直至任命永久继任者、公司停止运营，或董事会就高管任命采取其他行动。
- None.
- CEO and CFO simultaneously resigning
- Limited operating capital available
- Uncertain prospects to continue as going concern
- Company has only one Director
BENTONVILLE, Ark., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) today announced that its Chief Executive Officer and Chief Financial Officer has resigned, effective September 30, 2025, for personal reasons. The resignation was not requested by the Company.
Murray Fleming, the Company’s sole Director, will perform the functions of Chief Executive Officer and Chief Financial Officer in his capacity as Director to provide administrative continuity and will assist shareholders in identifying new officers. This service will continue until one of the following occurs:
- Permanent successors, if any, are appointed.
- The Company determines to wind down and cease operations.
- The Board takes further action with respect to officer appointments.
There were no disagreements with the Company on any matter relating to its operations, policies, or practices.
The Company confirms that day-to-day operations will continue under the Director’s oversight; however, the Company has limited operating capital and uncertain prospects to continue as a going concern.
For further information, please contact:
info@glucosehealthinc.com
FAQ
Why did Glucose Health's CEO and CFO resign in September 2025?
Who will lead Glucose Health (GLUC) after the CEO and CFO resignation?
What is Glucose Health's (GLUC) financial status as of September 2025?
What are the conditions for ending Murray Fleming's interim leadership at Glucose Health?
Were there any disagreements between the departing officers and Glucose Health?
